DICP OpenIR
学科主题化学其他学科
Molecular Magnetic Resonance Imaging of Prostate Tumor Using Peptide Targeted Nanoglobular Contrast Agent
Tan MQ(谭明乾); Ma XJ(马小军); Lv ZR(吕正荣); MingqianTan
会议文集会议资料汇编
会议名称International Development and Research Institution Mission to Chongqing-International Conference of Nanobiotechnology and Microsystem Innovative Industrialization
会议日期2011-10-22
2011
会议地点重庆
其他题名多肽靶向球状造影剂用于前列腺癌核磁共振分子成像
页码37-0
出版者待补充
出版地待补充
合作性质分会特邀报告
部门归属1802
主办者中国科技部,重庆市人民政府
英文摘要Molecular imaging of tumor biomarkers has a potential to accurately diagnose malignant tumors at its earliest stage. Molecular MRI of cancer-related fibronectin in tumor stroma was investigated with a targeted contrast agent (CA) in a mouse orthotopic PC-3 prostate cancer model. A CLT1 (CGLIIQKNEC) cyclic peptide targeted generation 2 nanoglobular Gd-DOTA monoamide conjugate (CLT1-targeted MRI CA) was used for imaging fibronectin in tumor stroma. A conjugate of peptide KAREC was used as a control MRI CA (non-targeted control). Orthotopic PC-3 prostate tumors were established in the prostate of athymic nude male mice. Tumor binding of CLT1 peptide was examined by fluorescence imaging with fluorescently tagged peptide probes. MR imaging was performed with the mice bearing orthotopic PC-3 prostate tumors on a Bruker Biospec 7T animal MRI scanner. CLT1 showed specific binding in the prostate tumor without binding in normal tissues. The control peptide had little binding in both normal and tumor tissues. The CLT1-targeted MRI CA resulted in stronger contrast enhancement in the tumor tissue than the control MRI CA. CLT1-targeted MRI CA is a promising molecular MRI contrast agent for fibronectin in the tumor stroma. It has a potential for the diagnosis and assessing prognosis of malignant tumors with MRI.; Molecular imaging of tumor biomarkers has a potential to accurately diagnose malignant tumors at its earliest stage. Molecular MRI of cancer-related fibronectin in tumor stroma was investigated with a targeted contrast agent (CA) in a mouse orthotopic PC-3 prostate cancer model. A CLT1 (CGLIIQKNEC) cyclic peptide targeted generation 2 nanoglobular Gd-DOTA monoamide conjugate (CLT1-targeted MRI CA) was used for imaging fibronectin in tumor stroma. A conjugate of peptide KAREC was used as a control MRI CA (non-targeted control). Orthotopic PC-3 prostate tumors were established in the prostate of athymic nude male mice. Tumor binding of CLT1 peptide was examined by fluorescence imaging with fluorescently tagged peptide probes. MR imaging was performed with the mice bearing orthotopic PC-3 prostate tumors on a Bruker Biospec 7T animal MRI scanner. CLT1 showed specific binding in the prostate tumor without binding in normal tissues. The control peptide had little binding in both normal and tumor tissues. The CLT1-targeted MRI CA resulted in stronger contrast enhancement in the tumor tissue than the control MRI CA. CLT1-targeted MRI CA is a promising molecular MRI contrast agent for fibronectin in the tumor stroma. It has a potential for the diagnosis and assessing prognosis of malignant tumors with MRI.
文献类型会议论文
条目标识符http://cas-ir.dicp.ac.cn/handle/321008/116113
专题中国科学院大连化学物理研究所
通讯作者MingqianTan
推荐引用方式
GB/T 7714
Tan MQ,Ma XJ,Lv ZR,et al. Molecular Magnetic Resonance Imaging of Prostate Tumor Using Peptide Targeted Nanoglobular Contrast Agent[C]. 待补充:待补充,2011:37-0.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[谭明乾]的文章
[马小军]的文章
[吕正荣]的文章
百度学术
百度学术中相似的文章
[谭明乾]的文章
[马小军]的文章
[吕正荣]的文章
必应学术
必应学术中相似的文章
[谭明乾]的文章
[马小军]的文章
[吕正荣]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。